Literature DB >> 29921719

Novel Approaches to Control of the Alternative Complement Pathway for the Treatment of C3 Glomerulopathies.

Mohamed R Daha1, Marc Seelen2.   

Abstract

Entities:  

Keywords:  C3G; complement; inhibitor

Mesh：

Substances：

Year:  2018        PMID： 29921719      PMCID： PMC6065089          DOI： 10.1681/ASN.2018050554

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  4 in total

1.  The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.

Authors:  Stefan Michelfelder; Friedericke Fischer; Astrid Wäldin; Kim V Hörle; Martin Pohl; Juliana Parsons; Ralf Reski; Eva L Decker; Peter F Zipfel; Christine Skerka; Karsten Häffner
Journal:  J Am Soc Nephrol       Date:  2018-01-15       Impact factor: 10.121

Review 2.  The renaissance of complement therapeutics.

Authors:  Daniel Ricklin; Dimitrios C Mastellos; Edimara S Reis; John D Lambris
Journal:  Nat Rev Nephrol       Date:  2017-12-04       Impact factor: 28.314

3.  Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.

Authors:  Xiaoxu Wang; Menno Van Lookeren Campagne; Kenneth J Katschke; Damodar Gullipalli; Takashi Miwa; Yoshiyasu Ueda; Yuan Wang; Matthew Palmer; Guolan Xing; Wen-Chao Song
Journal:  J Am Soc Nephrol       Date:  2018-06-12       Impact factor: 10.121

4.  An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.

Authors:  Yi Yang; Harriet Denton; Owen R Davies; Kate Smith-Jackson; Heather Kerr; Andrew P Herbert; Paul N Barlow; Matthew C Pickering; Kevin J Marchbank
Journal:  J Am Soc Nephrol       Date:  2018-03-27       Impact factor: 10.121
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.